Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahmoud Ghandi

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cell Reports Methods|June 16, 2023
Targeted <i>in silico</i> characterization of fusion transcripts in tumor and normal tissues via FusionInspectorBrian J Haas, Alexander Dobin, Mahmoud Ghandi, et al.
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2016
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancersPeter Tsvetkov, Ethan Sokol, Dexter Jin, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
Nature Medicine|February 25, 2014
ARID1B is a specific vulnerability in ARID1A-mutant cancersKatherine C Helming, Xiaofeng Wang, Boris G Wilson, et al.
Cell Reports|August 15, 2024
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Nature Communications|August 29, 2020
Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of actionJames M McFarland, Brenton R Paolella, Allison Warren, et al.
Cell|January 25, 2020
Quantitative Proteomics of the Cancer Cell Line EncyclopediaDavid P Nusinow, John Szpyt, Mahmoud Ghandi, et al.
Blood|June 22, 2016
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutationsAbner Louissaint, Kristian T Schafernak, Julia T Geyer, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cell Reports Methods|June 16, 2023
Targeted <i>in silico</i> characterization of fusion transcripts in tumor and normal tissues via FusionInspectorBrian J Haas, Alexander Dobin, Mahmoud Ghandi, et al.
Cancer Discovery|September 9, 2016
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast CancerXiuning Le, Rajee Antony, Pedram Razavi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 29, 2016
Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancersPeter Tsvetkov, Ethan Sokol, Dexter Jin, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
Nature Medicine|February 25, 2014
ARID1B is a specific vulnerability in ARID1A-mutant cancersKatherine C Helming, Xiaofeng Wang, Boris G Wilson, et al.
Cell Reports|August 15, 2024
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4Hannah N W Weinstein, Kevin Hu, Lisa Fish, et al.
The Journal of Clinical Investigation|August 23, 2019
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistanceKatsuhiro Togami, Timothy Pastika, Jason Stephansky, et al.
Nature Communications|August 29, 2020
Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of actionJames M McFarland, Brenton R Paolella, Allison Warren, et al.
Cell|January 25, 2020
Quantitative Proteomics of the Cancer Cell Line EncyclopediaDavid P Nusinow, John Szpyt, Mahmoud Ghandi, et al.
Blood|June 22, 2016
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutationsAbner Louissaint, Kristian T Schafernak, Julia T Geyer, et al.
Pageof 4